StockData
Roivant Sciences Ltd. logo

Roivant Sciences Ltd. (ROIV) company profile

ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$38.71+0.10 (+0.26%)

Close on Nov 17, 2026Market cap $27.96BP/E –Yield –

About Roivant Sciences

Pharmaceutical Preparations, SIC 2834

Roivant is a biopharmaceutical company that focuses on accelerating the development and commercialization of medicines across diverse therapeutic areas. The company organizes its operations through specialized, nimble subsidiary companies known as “Vants,” while also incubating early-stage discovery ventures and complementary health technology businesses. Its clinical pipeline centers on therapeutic candidates such as brepocitinib, an oral small-molecule dual inhibitor targeting inflammatory and immune conditions; IMVT-1402, a fully human monoclonal antibody directed against IgG-mediated autoimmune indications; and mosliciguat, an inhaled formulation under evaluation for pulmonary vascular disorders. Roivant targets patient populations suffering from severe autoimmune, dermatological, rheumatological, and respiratory conditions where current medical options remain inadequate.

The company advances its clinical programs within the United States, conducting registrational trials and pursuing regulatory submissions across specialized clinical networks. Beyond therapeutics development, Roivant supports discovery and software-driven initiatives that integrate computational workflows into biopharma processes. The company does not operate commercial retail stores, and the provided text does not state its corporate headquarters location.

Summary of the business section of Roivant Sciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Roivant Sciences Ltd.
Founded
2014
Headquarters
London, United Kingdom
Address
7th Floor, 50 Broadway SW1H 0DB
Phone
(441) 295-5950
Employees
721, Mar 31, 2026
Industry
Pharmaceutical Preparations
Incorporated in
D0
Fiscal year ends
March 31
Auditor
Ernst & Young LLP, Iselin, New Jersey

Stock & identifiers

Ticker
ROIV
Exchange
Nasdaq
IPO date
Dec 8, 2020
Shares outstanding
722M, Jul 31, 2026
Public float
$9.80B, Sep 30, 2025
Filer category
Large accelerated filer
SEC CIK
1635088
CUSIP
G76279101
FIGI
BBG007STW2B8
Share class FIGI
BBG007STW2C7
LEI
549300DL466NY5J6U724
EIN
98-1173944

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Mayukh SukhatmePresident & CIO, Director20,054,401
Matthew GlineCEO, Director16,391,229
Richard PulikCFO222,046
Eric VenkerPresident & Immunovant CEO811,211
Frank TortiPresident and Vant Chair12,306,950
Jennifer HumesChief Accounting Officer106,419
Rakhi KumarChief Accounting Officer162,306
James C. MomtazeeDirector112,265
Epperly Melissa B,Director15,351
Ilan OrenDirector124,490
Daniel Allen GoldDirector22,654,981
Keith S. ManchesterDirector15,442,623
Meghan FitzgeraldDirector41,162

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$3.10M$382.44M$38.29M$561$145
FY2024$163.29M$120.29M$54.97M$204$104
FY2023$738.19K$45.54M$4.74M$213$108
FY2022$48.98M$97.62M$48.71M$149$100

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
Matthew Gline
Chief Executive Officer
$725.00K$2.36M––$11.94K$3.10M-98%
Richard Pulik
Chief Financial Officer
$450.88K$1.28M$1.42M$1.02M$24.02K$4.19M+2%
Mayukh Sukhatme
President and Chief Investment Officer
$550.00K$704.00K––$22.66K$1.28M-99%
Eric Venker
President and Immunovant CEO
$75.00K$1.90M$2.26M–$20.16M$24.40M+107%
Frank Torti
President and Vant Chair
$725.00K$8.43M$109.34M–$4.81M$123.30M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of March 31, 2026, we and our subsidiaries had approximately 721 full-time employees, including 659 in the U.S.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?